CPD Login
Diabetic nephropathy complexities
Hypertension is common among patients with diabetes. Hypertension increases their risk of chronic kidney disease (CKD) onset and progression, as…
Efficacy of fixed-dose, triple therapy in essential hypertension
Hypertension is the leading cause of mortality worldwide, accounting for more than 10 million deaths every year. The majority of…
Alirocumab reduces CVD risk in patients who fail to achieve LDL-C goals
The prevalence of dyslipidaemia varies from region to region, but it is estimated that about half of the adult population…
ACS one of the leading causes of disability in people of all ages
Ischaemic heart disease – now referred to as acute coronary syndrome (ACS) –is ranked second after neonatal disorders as the…
7 key messages from the ECS about adult CHD
Although the prevalence of severe congenital heart defects (CHD) is declining worldwide, the overall prevalence – especially in adult patients…
Sanofi and Regeneron announce approval of alirocumab for the treatment of hypercholesterolaemia in SA
Sanofi and Regeneron Pharmaceuticals, Inc. have announced that the South African Health Products Regulatory Agency (SAHPRA) has approved alirocumab for…
Acquired haemophilia: Rare, but fatal
Acquired haemophilia A (AHA) – also known as acquired factor VIII inhibitor disorder – is a rare bleeding condition (one…
Increased cardiovascular residual risk in patients with diabetes due to atherogenic dyslipidaemia
Cardiovascular disease (CVD) and type 2 diabetes (T2DM) is on the increase worldwide and clinicians need to be aware of…
BP control crucial to prevent overt HF
More than 7.5 million deaths per year are attributable to hypertension.
Small-dense LDL and triglycerides in atherogenic dyslipidaemia
Cardiovascular disease (CVD) and Type 2 diabetes is on the increase worldwide and clinicians need to be aware of the…
Vasculitis in the heart: Late complication of COVID-19
A case report has emerged of a 31-year-old woman with heart damage almost two weeks after hospital discharge.
Diuretics for hypertension
Since diuretics are an important treatment for hypertension, they have an important role in the South African healthcare system, where…
Management of CV risk factors in patients with Covid-19
The Covid-19 causative agent, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), affects multiple organ systems, especially the lungs and heart.…
Evolocumab and CVD: What you need to know
Low-density lipoprotein (LDL) cholesterol is a well-established and modifiable risk factor for cardiovascular disease.
Different strategies to prevent and treat VTE in stroke patients
Arrhythmias – often described as ‘hijackers’ of the heart’s rhythm and pump functions, cause the heart to either beat too…
Which dual combinations work best in Black hypertensive patients?
Since the 1980s, systolic blood pressure (SBP) has increased exponentially in Black patients and currently, the highest prevalence of hypertension…
Two-thirds of Global South hypertension sufferers missing treatment
Healthcare in low- and middle-income countries is poorly prepared for the increasing number of people with high blood pressure, with…
Use of ACEIs, ARBs in Covid-19 patients
Use of ACEIs (angiotensin-converting enzyme inhibitors) and ARBs (angiotensin II receptor blockers) is a major concern for clinicians treating Covid-19…
Enalapril dosing recommendations
Heart disease remains the leading cause of death worldwide. Pharmacological interventions have mitigated risk factors related to heart disease to…
Controlling hypertension during the COVID-19 pandemic
How should clinicians navigate clinical uncertainty for patients who are taking angiotensinconverting-enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs)?
